SILu™Prot IGFBP7 Insulin-like growth factor-binding protein 7 human
SIGMA/MSST0037 - recombinant, expressed in HEK 293 cells, SIL MS Protein Standard, 13C and 15N-labeled
Synonym: IBP-7; IGF-binding protein 7; IGF-bindingprotein7; IGFBP-7; IGFBP-rP1; MAC25 protein; PGI2-stimulating factor; Prostacyclin-
Product Type: Chemical
SILuProt products are stable isotope-labeled full length proteins designed to be used as mass spectrometry internal standards for quantitative proteomics. Introduction of an internal SILuProt standard at the beginning of the MS workflow minimizes variations in quantification due to protein extraction, fractionation, enrichment, proteolysis and analysis
| assay | ≥98% (SDS-PAGE) |
| biological source | human |
| form | lyophilized powder |
| potency | ≥98 Heavy amino acids incorporation efficiency by MS |
| Quality Level | 200  |
| recombinant | expressed in HEK 293 cells |
| storage temp. | −20°C |
| suitability | suitable for mass spectrometry (standard) |
| technique(s) | mass spectrometry (MS): suitable |
| UniProt accession no. | Q16270  |
| Biochem/physiol Actions: | SILu™Prot IGFBP7 is a recombinant, stable isotope-labeled human IGFBP7 which incorporates [13C6, 15N4]-Arginine and [13C6, 15N2]-Lysine. Expressed in human 293 cells, it is designed to be used as an internal standard for bioanalysis of IGFBP7 in mass-spectrometry. SILu Prot IGFBP7 is a protein consisting of 267 amino acids (including an N-terminal polyhistidine tag), with a calculated molecular mass of 28 kDa. |
| General description: | IGFBP7 regulates the availability of insulin-like growth factors (IGFs) in tissue, and modulates IGF binding to its receptors. IGFBP7 binds to IGF with high affinity. Several studies have shown the involvement of IGFBP7 in Acute Kidney Injury (AKI), where its levels can predict patients at risk for developing AKI. When combined with TIMP-2, the accuracy of AKI risk prediction is further increased. Urinary [TIMP-2]×[IGFBP7] test sufficiently detects patients with risk of AKI after major non-cardiac surgery. In addition, Urinary [TIMP-2]×[IGFBP7] serves as a sensitive and specific biomarker to predict AKI early after cardiac surgery and to predict renal recovery. |
| Immunogen: | HHHHHHHHGGQSSSDTCGPCEPASC |
| Legal Information: | SILu is a trademark of Sigma-Aldrich Co. LLC |
| Legal Information: | This product is licensed under U.S. Patent No. 7,396,688 and foreign counterparts from E. I. du Pont de Nemours and Company. The purchase of this product conveys to the buyer the nontransferable right to use the purchased amount of the product for research and development only, including services for a third party for consideration. The buyer cannot sell or otherwise transfer this product, its components or materials made using this product or its components to a third party. Information about licenses for excluded uses is available from: E. I. du Pont de Nemours and Company; Attn: Associate Director, Commercial Development; DuPont Experimental Station E268; 200 Powdermill Rd.; Wilmington, DE 19803; 1-877-881-9787 (voice), 1-302-695-1437 (fax), licensing@dupont.com. |
| Physical form: | Supplied as a lyophilized powder containing phosphate buffered saline. |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 2 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (SDS-PAGE) |
| Storage Temp. | −20°C |
| UNSPSC | 23201100 |